Viking Therapeutics (VKTX) Reports In-Line Q2 EPS

Viking Therapeutics (NASDAQ: VKTX) reported Q2 EPS of ($0.19), in-line with the analyst estimate of ($0.19).

For earnings history and earnings-related data on Viking Therapeutics (VKTX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c